Advances in Immunotherapy of Allergic Diseases II

Dear Colleagues,

The continuous advancement of biomedical sciences has offered an extreme boost in the diagnosis and therapy of allergic diseases. Allergen immunotherapy (AIT) remains the only causative treatment of IgE-mediated hypersensitivity reactions and represents an example of precision medicine, offered by allergologists. Therapeutical advances such as the introduction of depot extracts for subcutaneous AIT and the use of sublingual immunotherapy have contributed to the safety and efficiency of AIT for a long time. Lately, the emerging intralymphatic route is a novel, much promising approach for AIT. We are also witnessing fast steps in the establishment of food immunotherapy with a variety of proposed protocols, clinical trials, and the approval of the first commercial products for the induction of food tolerance.

After a successful first issue on “Advances in Immunotherapy of Allergic Diseases”, this second Special Issue aims to collect selected reviews and original studies on AIT. We welcome studies and clinical trials on allergens, vaccines, and adjuvants, or on novel desensitization products, papers on new treatment protocols, or on practical issues of AIT. Reviews as well as original papers on the humoral and cellular mechanisms involved in all types of AIT are also welcomed.

We look forward to your contributions to this second Cells Special Edition on AIT.

Dr. Constantinos Pitsios
Dr. Caterina Chliva
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cells is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.